Dosing Protocol Key Efficacy Data The SURMOUNT clinical trial program established tirzepatide as the most effective GLP-1 weight loss agent currently available: SURMOUNT-1 (adults without diabetes): Mean weight loss of 20.9% (10 mg), 24.0% (15 mg) at 72 weeks versus 3.1% placebo (Jastreboff et al., NEJM , 2022) SURMOUNT-2 (adults with type 2 diabetes): Mean weight loss of 12.8% (10 mg), 14.7% (15 mg) at 72 weeks (Garvey et al., Lancet , 2023) SURMOUNT-3 (after intensive lifestyle intervention lead-in): Mean total weight loss of 26.6% with tirzepatide 15 mg (Wadden et al., Nature Medicine , 2023) SURMOUNT-4 (withdrawal study): Patients who discontinued tirzepatide after 36 weeks regained approximately two-thirds of lost weight by week 88, demonstrating the chronic disease nature of obesity and the need for ongoing treatment (Aronne et al., JAMA , 2024) Why Dual Agonism Matters The GIP receptor activation in tirzepatide produces additive effects beyond GLP-1 agonism alone
Ann N Y Acad Sci 2008;1127:92-100 DHooghe TM, Debrock S, Hill JA, Meuleman C
People arent just seeking weight loss
Consequently, a range of innovative nanomaterial-based drugs has been developed, distinct from conventional medications [226]
The health questionnaire takes about 15 minutes
While the manufacturer recommends injecting Ozempic into the abdomen, other options, like the arms or thighs, are also viable
